Dramatic Microbiome Change Predicts Weight Loss Effectiveness After Metabolic Bariatric Surgery
November 18, 2024 / Gut Microbiome / Weight Loss / Bariatric Surgery Outcomes / Metabolic Surgery Research / Weight Management / Obesity
A Cleveland Clinic study links dramatic gut microbiome changes post-bariatric surgery to greater long-term weight loss, suggesting predictive potential and opportunities for early intervention. Findings highlight personalized approaches via probiotics, dietary modifications, and microbiome-driven therapies.
Adipose tissue retains an epigenetic memory of obesity after weight loss
November 18, 2024 / Obesity Epigenetic Memory / Yo-yo Dieting Mechanisms / Long-term Obesity Management / Cellular Memory
Adipose tissue retains obesity-induced epigenetic and transcriptional changes even after significant weight loss, promoting rapid weight regain and metabolic dysfunction. Targeting these changes may enhance long-term weight management and reduce the “yo-yo” effect.
The association between metabolic syndrome and lung cancer risk: a Mendelian randomization study
November 18, 2024 / Metabolic Syndrome / Lung Cancer Risk / Obesity / Cancer Epidemiologys
This Mendelian randomization study establishes a causal link between metabolic syndrome (MetS) and increased risk of lung cancer, particularly squamous cell and small cell subtypes. Key mediators include smoking, obesity, type 2 diabetes, and alcohol use.
Boston Pharma Carves Out Monthly Treatment Niche in MASH With Strong Phase II Data
November 18, 2024 / MASH / Metabolic Dysfunction Steatohepatitis Treatment / Fibrosis Improvement / Clinical Trialn
Boston Pharma’s efimosfermin alfa, a monthly FGF21 analog, demonstrated significant improvements in fibrosis and MASH resolution in Phase II trials. With strong safety and efficacy, it offers a competitive edge in the MASH treatment landscape.
Exploring the protective effects of HSD17B13 in hepatic steatosis
November 8, 2024 / Liver Disease / Hepatic Steatosis Treatment / MASH / ALD Genetic Protection / Liver Fibrosis
The HSD17B13 gene, particularly its rs72613567 variant, shows protective effects against liver disease progression, including reduced risk of fibrosis and hepatocellular carcinoma in MASH and ALD. Targeting HSD17B13 offers potential for new liver disease therapies.
Revolutionary obesity and diabetes treatment burns energy and reduces appetite without side effects
November 16, 2024 / GLP-1 Therapies for Obesity / Dual Treatment and Obesity / GCGR / Weight Loss / Diabetes Management
Long-acting incretin therapies like GLP-1 have transformed obesity and type 2 diabetes care, but limited efficacy in patients with both conditions highlights the need for new treatments. Emerging GCGR agonists could address energy expenditure deficits safely.
ACBP/DBI neutralization for the experimental treatment of fatty liver disease
November 16, 2024 / ACBP/DBI Neutralization Therapy / Fatty Liver Disease Treatment / MASH / Liver Fibrosis Intervention
Neutralizing ACBP/DBI with monoclonal antibodies reduced liver damage, inflammation, and fibrosis in preclinical MASH and liver fibrosis models, highlighting ACBP/DBI as a promising therapeutic target for fatty liver disease treatment.
Association between subjective walking speed and metabolic diseases in individuals with obesity: a cross-sectional analysis
November 15, 2024 / Obesity / Walking Speed / Metabolic Disease Prevention / Diabetes Risk / Hypertension
A study links faster subjective walking speed in individuals with obesity to reduced risk of metabolic diseases, including diabetes, hypertension, and dyslipidemia, highlighting a simple self-reported measure as a potential tool for early prevention efforts.
Weight Loss Breakthrough: Scientists Discover Natural Compound That Suppresses Appetite
November 15, 2024 / BHB-Phe Appetite Regulation / Natural Weight Loss / Obesity Metabolic Pathways / Brain Neurons
Scientists identified BHB-Phe, a natural compound regulating appetite and weight by activating specific brain neurons. This discovery offers insights into metabolic pathways and potential non-restrictive obesity treatments, marking a breakthrough in appetite control research.
SLU Study: Immune Dysfunction Increases Cancer Risk in Obese Populations
November 15, 2024 / Obesity / Immune Dysfunction / T-cell Ddysfunction and Cancer Risk / Immune Surveillance in Obesity / Cancer Research
Saint Louis University researchers link obesity-induced T-cell dysfunction to increased cancer risk, impairing immune surveillance. Findings suggest obesity weakens tumor detection, yet enhances immunotherapy effectiveness, highlighting new avenues for improving cancer treatments in obese patients.
Effects of exercise and dietary interventions on asprosin, leptin, and lipid metabolism in males with abdominal obesity, a randomized controlled trial
November 15, 2024 / Abdominal Obesity Treatment / Diet Interventions / Lipid Metabolism / Asprosin
Combining aerobic-resistance exercise with a high-protein, low-glycemic diet significantly reduced asprosin, leptin, body fat, and cholesterol while improving fat-free mass in males with abdominal obesity, outperforming exercise alone in metabolic benefits over six weeks.
Unraveling the metabolic activities of bioactive compounds on cellular models of hepatosteatosis and adipogenesis through docking analysis with PPARs
November 15, 2024 / Hepatic Steatosis Treatment / Lipid Metabolism / Obesity-Related Liver Disease Therapy
This study evaluated five bioactive compounds for their effects on hepatic steatosis and adipogenesis. All compounds reduced lipid accumulation and oxidative stress. Molecular docking revealed varied binding affinities to PPARα and PPARγ, pivotal regulators of lipid metabolism.
Metsera lands £215m to accelerate obesity and metabolic disease pipeline
November 15, 2024 / Obesity Treatment Innovation / GLP-1 Receptor Agonist Development / Metabolic Disease Pipeline Funding
Metsera raised £215M to advance its innovative obesity and metabolic disease therapies, including ultra-long-acting GLP-1 receptor agonists and amylin analogs for monthly dosing, leveraging cutting-edge platforms for oral peptides and enhanced treatment efficacy.
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024
November 15, 2024 / Pemvidutide MASLD Trial Results / GLP-1 / MASH Treatment
Altimmune’s pemvidutide, a GLP-1/glucagon dual receptor agonist, showed significant reductions in liver fat, inflammatory lipids, and atherogenic LDL particles in a Phase 1b MASLD trial, addressing both liver and cardiovascular risks associated with the disease.
ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update
November 14, 2024 / ZyVersa / Inflammation Therapy / Obesity / Diabetic Kidney Disease / Semaglutide Combination Therapy / Chronic Inflammation Obesity Treatment
ZyVersa advances its pipeline with a Phase 2a trial for VAR 200 in diabetic kidney disease (Q1-2025) and obesity-focused IC 100 studies. IC 100 targets chronic inflammation via multiple inflammasomes, offering potential breakthroughs in obesity-related complications.
People with kidney disease, diabetes may develop heart disease 28 years earlier
November 14, 2024 / CKM Syndrome Cardiovascular Risk / Early Heart Disease in Diabetes / Chronic Kidney Disease / CVD / Heart Risk Prevention
Chronic kidney disease and type 2 diabetes elevate cardiovascular disease risk 8–28 years earlier, driven by inflammation, hypertension, and atherosclerosis. Early detection and intervention guided by CKM syndrome insights may significantly improve outcomes.
Fatty Liver Disease Now Affects 4 in 10 U.S. Adults
November 13, 2024 / Fatty Liver Disease Prevalence / Obesity / Liver Health / MASLD / Hispanic Health
Fatty liver disease affects 42% of U.S. adults, driven by obesity and diabetes, with Hispanic adults at highest risk. Prevention through lifestyle changes is critical to reduce its prevalence and severe complications, including liver failure.
Metabolic Compound Found to Regulate Appetite and Body Weight
November 13, 2024 / BHB-Phe Appetite Regulation / Ketones / Weight Loss / Obesity Metabolic Pathways / Hypothalamic Neurons
Researchers identified BHB-Phe, a compound influencing appetite and body weight by activating hypothalamic neurons. Reduced BHB-Phe production leads to increased food intake and weight gain, offering potential therapeutic pathways for obesity management.
Researchers Suggest Stress Hormones Explain How Obesity Causes Diabetes
November 12, 2024 / Stress Hormones / Diabetes / Obesity / Insulin Resistance / Metabolic Disease Prevention
Rutgers researchers reveal stress hormones, not impaired insulin signaling, as key drivers of obesity-induced diabetes. Heightened sympathetic nervous system activity counteracts insulin’s effects, offering insights into metabolic disease prevention via stress hormone-targeted therapies.
Researchers Discover New Metabolic Compound That Regulates Body Weight
November 12, 2024 / Weight Regulation / Ketones / Appetite Control / Obesity Treatment / Metabolic Health / Weight Loss
Researchers discovered BHB-Phe, a metabolic compound influencing appetite and body weight by activating specific neurons. This novel pathway, linked to ketone metabolism, may offer insights into obesity treatment without carbohydrate restriction, opening avenues for future therapeutic interventions.
Scientists discover novel metabolic compound that can regulate body weight
November 12, 2024 / BHB-Phe Metabolic Discovery / Obesity / Brain Neurons / Weight Loss Research / Obesity Therapy
Scientists identified BHB-Phe, a natural metabolic compound regulating appetite and body weight through specific brain neurons. This discovery offers potential therapeutic applications for obesity and diabetes, enabling weight management without dietary carbohydrate restriction.